Netherlands· NL-6d84f4fd79d1
Red Skin druppels
A medicinal product containing atropa bella-donna + rhus toxicodendron + urtica dioica, registered in Netherlands by Dossier B.V..
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ATROPA BELLA-DONNA + RHUS TOXICODENDRON + URTICA DIOICA
- Manufacturer
- Dossier B.V.
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id95375
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c35c9c57-e0b3-4464-9a7b-449d78e0a193 GET /v1/drugs/c35c9c57-e0b3-4464-9a7b-449d78e0a193?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Druppels voor oraal gebruik, oplossing",
"route": "Oraal gebruik",
"soort": "RVH",
"source": "cbg_meb",
"smpc_url": null,
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg95375",
"excipients": null,
"substances": [
"ATROPA BELLA-DONNA",
"RHUS TOXICODENDRON",
"URTICA DIOICA"
],
"leaflet_url": null,
"authorised_at": "2004/02/09",
"procedure_number": null,
"dispensing_status": "Uitsluitend apotheek of drogist",
"registration_number": "95375",
"additional_monitoring": "N"
}See everything about atropa bella-donna + rhus toxicodendron + urtica dioica.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.